EGFR and non-small cell lung carcinoma: Moreover, high PTEN expression seems to contribute to prolonged survival in gefitinib-treated NSCLC patients, while EGFR mutant patients with concomitant elevated PTEN expression showed the longest survival compared to other subgroups [102].